Compliance · The complete guide

IFDA (Iran)

TL;DR

Iran Food and Drug Administration (IFDA — سازمان غذا و دارو — Sazman-e Ghaza va Daru) — operating as autonomous deputy organisation of the Ministry of Health and Medical Education (MoHME — وزارت بهداشت، درمان و آموزش پزشکی — Vezarat-e Behdasht, Darman va Amuzesh-e Pezeshki) — is the Islamic Republic of Iran's national regulatory authority for human medicines + biologicals + biosimilars + advanced therapy medicinal products + vaccines + medical devices + IVDs + cosmetics + dietary supplements + food + traditional + complementary medicines + pharmacy practice + controlled substances + clinical trials across the entire territory of the Islamic Republic of Iran. The IFDA operates under the Law on Pharmaceutical Affairs 1334/1955 (قانون مربوط به مقررات امور پزشکی، دارویی و مواد خوراکی و آشامیدنی) + the Food, Drugs and Sanitary Materials Law 1346/1967 + the Law on the Establishment of the Iran Food and Drug Administration 1392/2013 + the Law on Anti-Smuggling of Goods and Currency 1392/2013 + the Counter-Narcotics Law (as amended) + MoHME Ministerial Decrees + IFDA Director-General Decrees + Pharmaceutical Affairs Office Procedures + IFDA Guidance Documents + Iranian Pharmacopoeia (Pharmacopoeia Iranica). The IFDA is headquartered in Tehran with substantial regional + provincial Vice-Chancellor for Food and Drug Affairs structures across all 31 Iranian provinces operating through Medical Sciences Universities. The IFDA is one of the largest + most operationally significant Middle Eastern pharmaceutical regulators + is a PIC/S Member (since 2018) + WHO PIDM Member + WHO PQ programme participant + ECO Member State (Economic Cooperation Organization) + maintains substantial WHO EMRO + ICH Observer + bilateral cooperation with Russian Roszdravnadzor (substantial EAEU bilateral pharmaceutical-trade) + Chinese NMPA (substantial Belt and Road Initiative pharmaceutical-trade) + Indian CDSCO (substantial pharmaceutical-trade) + Turkish TİTCK (regional EMEA neighbour) + Iraqi MoH + Syrian MoH + Pakistani DRAP + Afghan MoPH + Central Asian (Azerbaijan + Turkmenistan + Tajikistan) regulators reflecting Iran's regional pharmaceutical-trade position. This page covers the IFDA's regulatory architecture for Iranian + foreign manufacturers + sponsors targeting Iran (~88 million population, world's ~21st-largest economy by PPP, substantial regional pharmaceutical-manufacturing hub with ~120+ Iranian-domestic manufacturers + ~200+ pharmaceutical-manufacturing facilities covering ~97% of domestic consumption by volume + ~70% by value historically including Cinnagen + AryoGen + Sobhan + Osvah + Pars Daru + Tehran Chemie + Daru Pakhsh + Aburaihan + Loghman + Alborz Daru + Iran Hormone + Tofigh Daru + Razi Vaccine and Serum Research Institute + Pasteur Institute of Iran + Exir Pharmaceutical; substantial biotechnology + biosimilar industry — Cinnagen is one of the largest biosimilar manufacturers in EMRO; substantial sanctions-environment context under US OFAC + EU + UK OFSI sanctions including humanitarian-exemption General Licenses for medicines + medical devices + financial-channel compliance challenges; Persian (Farsi) + English overlay labelling, substantial Climate Zone II coastal Caspian + Persian Gulf + IVa interior + IVb arid Central Plateau stability requirements).

Reviewed May 24, 2026· By V5 Ultimate compliance team· 3,940 words · ~18 min read

01What the Iran FDA actually is

The Iran Food and Drug Administration (IFDA — سازمان غذا و دارو — Sazman-e Ghaza va Daru) — operating as autonomous deputy organisation of the Ministry of Health and Medical Education (MoHME) — is the Islamic Republic of Iran's national regulatory authority for human medicines + biologicals + biosimilars + advanced therapy medicinal products + vaccines + medical devices + IVDs + cosmetics + dietary supplements + food + traditional + complementary medicines + pharmacy practice + controlled substances + clinical trials. The IFDA was established as autonomous deputy organisation under the Law on the Establishment of the Iran Food and Drug Administration 1392/2013 + operates under the Law on Pharmaceutical Affairs 1334/1955 + Food, Drugs and Sanitary Materials Law 1346/1967 + Law on Anti-Smuggling of Goods and Currency 1392/2013 + Counter-Narcotics Law + MoHME Ministerial Decrees + IFDA Director-General Decrees + Pharmaceutical Affairs Office Procedures + IFDA Guidance Documents + Iranian Pharmacopoeia.

IFDA organisational structure includes:

Minister of Health and Medical Education (وزیر بهداشت، درمان و آموزش پزشکی) — political head; appointed by the President of the Islamic Republic.
Director-General of the IFDA (رئیس سازمان غذا و دارو) — IFDA head; appointed by the Minister at MoHME Deputy level.
Deputy Directors-General — operational deputies for Pharmaceutical Affairs + Medical Devices + Food + Cosmetics + Inspection + Pharmacovigilance + International Affairs + Administrative Affairs.
Pharmaceutical Affairs Office (اداره کل امور دارو و مواد تحت کنترل) — drug + biological + biosimilar + vaccine + ATMP + generic-medicine registration.
Pharmaceutical Inspection Office (اداره کل بازرسی) — GMP + GDP + GPP + GVP + GLP inspections of Iranian + foreign manufacturing facilities; PIC/S Member capability.
Medical Devices Office (اداره کل تجهیزات پزشکی) — medical-device + IVD registration substantively aligned with EU MDR + IVDR elements.
Pharmacy Practice Office (اداره کل امور داروخانه‌ها) — pharmacy + pharmaceutical-establishment licensing.
Cosmetics + Dietary Supplements Office — cosmetic-product notification + dietary-supplement notification.
Food Office (اداره کل نظارت بر مواد غذایی، آشامیدنی، آرایشی و بهداشتی) — food regulation.
Controlled Substances + Narcotics Office — narcotics + psychotropics framework coordination with INCB + Anti-Narcotics Headquarters + Iranian National Police + Iranian Customs.
Pharmacovigilance Centre (مرکز ثبت و بررسی عوارض ناخواسته داروها — ADR Centre) — WHO PIDM affiliated.
Clinical Trials Office — CTA + Ethics Committee + Medical Sciences University coordination.
Reference Laboratories — IFDA central reference laboratories + Razi Vaccine and Serum Research Institute (Karaj) + Pasteur Institute of Iran (Tehran) substantial vaccine + biological lot-release capacity with ISO/IEC 17025 + WHO PQ-Lab.
International Affairs Office — WHO + ICH + PIC/S + WHO EMRO + ECO + Roszdravnadzor + NMPA + CDSCO + TİTCK + bilateral coordination.
Provincial Vice-Chancellor for Food and Drug Affairs (معاونت غذا و دارو) — 31 provinces, operating through Medical Sciences Universities for inspection + pharmacovigilance + provincial pharmaceutical-establishment regulation.

Iran's distinctive regional pharmaceutical-hub context: Iran is one of the largest + most operationally significant Middle Eastern pharmaceutical regulators. The Islamic Republic of Iran is a substantial regional pharmaceutical-manufacturing hub with ~120+ Iranian-domestic manufacturers + ~200+ pharmaceutical-manufacturing facilities covering ~97% of domestic consumption by volume + ~70% by value historically. Iran has substantial biotechnology + biosimilar industry — Cinnagen (headquartered in Tehran) is one of the largest biosimilar manufacturers in EMRO + one of the substantial global biosimilar manufacturers; AryoGen Pharmed + Pooyesh Darou + Samenpharmed + Orchid Pharmed substantial biosimilar + biotechnology capacity. Iran has substantial vaccine-manufacturing capacity via Razi Vaccine and Serum Research Institute (Karaj — historical animal + human vaccine production) + Pasteur Institute of Iran (Tehran — substantial human vaccine + biological production including BCG + DTP + measles + rubella + hepatitis B + COVID-19 vaccines). Iran is uniquely positioned by substantial sanctions-environment context under US OFAC + EU + UK OFSI sanctions including humanitarian-exemption General Licenses for medicines + medical devices + financial-channel compliance challenges driving substantial domestic-manufacturing self-sufficiency policy + EAEU + Belt and Road + India + Türkiye + Iraq + Syria + Central Asia trade-partner reorientation. Iran's geographic + economic position at the crossroads of the Middle East + Central Asia + South Asia + Caucasus makes it operationally significant for foreign manufacturers + sponsors targeting EMRO + EAEU + Central Asian markets via sanctions-compliant pathways.

IFDA is distinct from + complementary to: the Iran Pharmacists Association (Anjoman-e Daru-sazan-e Iran — professional licensing body for individual pharmacists); the Iranian Medical Council (Nezam-e Pezeshki — physician + dentist + pharmacist + other-healthcare-professional licensing); the Syndicate of Iranian Pharmaceutical Industries (representing manufacturers); the Iranian Generic Pharmaceutical Manufacturers Association; the Anti-Narcotics Headquarters (Setad-e Mobarezeh ba Mavadd-e Mokhader); the Food and Drug Organization Insurance + Iranian Social Security Organization + Salamat Insurance pharmaceutical-reimbursement coordination; and substantial Iranian biopharmaceutical-research infrastructure including Tehran University of Medical Sciences + Shahid Beheshti University of Medical Sciences + Isfahan University of Medical Sciences + Mashhad University of Medical Sciences + Shiraz University of Medical Sciences + Tabriz University of Medical Sciences + Iran University of Medical Sciences + Royan Institute (stem cell + reproductive biology) + Pasteur Institute + Razi Institute. Iran's pharmaceutical environment is uniquely characterised by: substantial regional pharmaceutical-manufacturing hub status with ~97% domestic-volume self-sufficiency; substantial biotechnology + biosimilar industry led by Cinnagen + AryoGen; substantial vaccine-manufacturing capacity via Razi + Pasteur Institutes; substantial sanctions-environment context under US OFAC + EU + UK OFSI sanctions including humanitarian-exemption General Licenses; PIC/S Member status (since 2018) enabling substantial mutual-recognition; substantial WHO PQ programme participation; substantial EAEU + Belt and Road + India + Türkiye + Iraq + Syria + Afghan + Central Asian + Caucasus trade-partner reliance; substantial Climate Zone II coastal Caspian (Rasht + Sari + Anzali) + Persian Gulf (Bushehr + Bandar Abbas + Ahvaz) + IVa interior (Tehran + Isfahan + Shiraz + Mashhad + Tabriz) + IVb arid Central Plateau (Yazd + Kerman + Zahedan + Birjand) stability requirements; Persian (Farsi) labelling.

IFDA is a PIC/S Member (since 2018) + WHO PIDM Member + WHO PQ programme participant + ECO Member State + maintains substantial WHO EMRO + ICH Observer + bilateral cooperation with Russian Roszdravnadzor (substantial EAEU bilateral pharmaceutical-trade) + Chinese NMPA (substantial Belt and Road Initiative pharmaceutical-trade) + Indian CDSCO (substantial pharmaceutical-trade) + Turkish TİTCK (regional EMEA neighbour + PIC/S Member peer) + Iraqi MoH + Syrian MoH + Pakistani DRAP + Afghan MoPH + Central Asian (Azerbaijan + Turkmenistan + Tajikistan) regulators reflecting Iran's regional pharmaceutical-trade position + sanctions-environment supply-chain reorientation.

One sentence summary

Iran IFDA is the Islamic Republic of Iran's pharmaceutical + medical-device + cosmetic + dietary-supplement + food + pharmacy regulator operating as autonomous deputy organisation of MoHME under the Law on the Establishment of the Iran FDA 1392/2013 + Law on Pharmaceutical Affairs 1334/1955; is one of the largest + most operationally significant Middle Eastern pharmaceutical regulators; is a PIC/S Member (since 2018) + WHO PIDM Member + WHO PQ programme participant + ECO Member State + substantial regional pharmaceutical-manufacturing hub serving Iran (~88 million population, world's ~21st-largest economy by PPP, ~120+ Iranian-domestic manufacturers + ~200+ pharmaceutical-manufacturing facilities covering ~97% of domestic consumption by volume including Cinnagen + AryoGen + Sobhan + Osvah + Pars Daru + Tehran Chemie + Daru Pakhsh + Aburaihan + Loghman + Alborz Daru + Iran Hormone + Razi Vaccine and Serum Research Institute + Pasteur Institute of Iran + Exir Pharmaceutical, substantial biotechnology + biosimilar industry led by Cinnagen one of the largest EMRO biosimilar manufacturers, substantial sanctions-environment context under US OFAC + EU + UK OFSI sanctions with humanitarian-exemption General Licenses, substantial EAEU + Belt and Road + India + Türkiye + Iraq + Syria + Central Asia trade-partner reliance, Persian (Farsi) labelling, Climate Zone II coastal + IVa interior + IVb arid stability requirements).

02Iranian pharmaceutical regulatory framework

Iranian pharmaceutical regulation operates under a layered framework of Laws + MoHME Ministerial Decrees + IFDA Director-General Decrees + Pharmaceutical Affairs Office Procedures + IFDA Guidance Documents — incorporating substantial PIC/S GMP + ICH guideline + WHO TRS Annex elements:

Law on the Establishment of the Iran Food and Drug Administration 1392/2013 — IFDA establishment as autonomous deputy organisation of MoHME.
Law on Pharmaceutical Affairs 1334/1955 (قانون مربوط به مقررات امور پزشکی، دارویی و مواد خوراکی و آشامیدنی) — foundational pharmaceutical law.
Food, Drugs and Sanitary Materials Law 1346/1967 — overarching food + drug + sanitary-materials framework.
Law on Anti-Smuggling of Goods and Currency 1392/2013 — substantive anti-counterfeit + anti-smuggling enforcement framework.
Counter-Narcotics Law (as amended) — narcotics + psychotropics framework.
IFDA Drug Registration Regulation — substantive drug registration framework.
IFDA Medical Device Regulation — substantively incorporating EU MDR + IVDR + IMDRF elements.
IFDA Cosmetics Regulation — substantively incorporating EU Cosmetics Regulation elements.
IFDA GMP Guide — substantively aligned with PIC/S GMP Guide + ICH Q7 + WHO TRS 986 Annex 2 + EU GMP elements.
IFDA GDP Guide — substantively aligned with WHO GDP + EU GDP elements.
IFDA GCP Guide — substantively aligned with ICH E6(R2).
IFDA GVP Guide — substantively aligned with ICH E2 + WHO PV guidance + EU GVP elements.
Pharmacopoeia recognition — Iranian Pharmacopoeia (Pharmacopoeia Iranica) + recognises European Pharmacopoeia + British Pharmacopoeia + USP + Indian Pharmacopoeia + Russian Pharmacopoeia + Chinese Pharmacopoeia.
Iranian National Essential Medicines List (IRNL — فهرست رسمی داروهای ایران) — substantively aligned with WHO Essential Medicines List + Food and Drug Organization Insurance + Iranian Social Security Organization + Salamat Insurance Reimbursement List.
Variations + 5-year Drug Registration Renewal framework.
Pricing Decree — substantive pricing-control framework via IFDA Pricing Commission + reference-pricing methodology.
Sanctions Environment Operational Framework — substantial sanctions-environment compliance framework under US OFAC + EU + UK OFSI sanctions including humanitarian-exemption General Licenses for medicines + medical devices + financial-channel compliance.
Local-Industry-Protected Status Framework — distinctive Iranian-domestic pharmaceutical-manufacturing localisation policy historically restricting registration where Iranian-domestic equivalents exist.

03Drug + biological registration pathways at the IFDA

Pathway	Use case	Clock + content
New Drug Registration	First-in-Iran new chemical entity / new biological / new indication; full IFDA Pharmaceutical Affairs Office scientific review + Drug Registration Commission opinion + GMP inspection where required.	IFDA target review: 270-360 calendar days for new drug registration; subject to clock-stops for company-response.
Generic Drug Registration	Generic version of registered Reference Drug; bioequivalence study where required per IFDA BE Guidance.	IFDA target review: 180-270 calendar days for generic registration; substantially reduced for EMA + SRA-approved generics.
Biosimilar Registration	Biosimilar version of registered reference biological; per IFDA + EMA biosimilar guidance; substantial Iranian biosimilar-industry context with Cinnagen + AryoGen leadership.	IFDA target review: 270-360 calendar days; comparability + clinical pathway substantively aligned with EMA + WHO biosimilar guidance.
Vaccine Registration	Vaccines for human use including Iranian National Immunisation Programme + travel + pandemic vaccines; substantial Iranian-domestic vaccine-manufacturing capacity via Razi + Pasteur Institutes.	IFDA target review: 180-360 calendar days; EMA + WHO PQ + Chinese NMPA + Russian Roszdravnadzor + Indian CDSCO reliance accepted; substantial Iranian-domestic vaccine-manufacturing capacity.
ATMP Registration	Advanced Therapy Medicinal Products (gene therapy, cell therapy, tissue-engineered products); per IFDA + EMA + Royan Institute ATMP guidance; substantial Iranian stem-cell + cell-therapy research capacity.	IFDA target review: 270-360 calendar days; comparability + clinical pathway substantively aligned with EMA ATMP framework.
SRA + WHO PQ Reliance	Reliance on EMA + FDA + Health Canada + TGA + Swissmedic + MHRA + MFDS + WHO PQ decisions; subject to sanctions-environment compliance.	IFDA target review: substantially reduced timeline for SRA + WHO PQ-approved products subject to sanctions-environment compliance.
WHO PQ Programme Participation	Iranian-manufactured medicines + vaccines + biosimilars submitted to WHO PQ for substantial UN-agency humanitarian procurement + LMIC market access notably for Cinnagen + AryoGen biosimilars + Razi + Pasteur Institutes vaccines.	Substantial Iranian-domestic manufacturer WHO PQ engagement for UN-agency humanitarian procurement opportunities.
Local-Industry-Protected Status Pathway	Distinctive Iranian-domestic pharmaceutical-manufacturing localisation policy historically restricting registration where Iranian-domestic equivalents exist + supporting Iranian-domestic manufacturing investment + technology transfer.	IFDA + Syndicate of Iranian Pharmaceutical Industries coordinated review; substantial preferential treatment for Iranian-localised products.
Trade-Partner Reliance	Substantial trade-partner reliance pathways with Russian Roszdravnadzor + Chinese NMPA + Indian CDSCO + Turkish TİTCK + Pakistani DRAP reflecting sanctions-environment trade-partner reorientation.	IFDA target review: substantially reduced timeline for trade-partner approved products under bilateral arrangements.
Variations + 5-year Renewal	Variations + mandatory 5-year renewal of registration.	Variations 30-180 calendar days; renewal 90-180 calendar days.
Clinical Trial Application (CTA)	Iranian clinical trials require IFDA CTA + Ethics Committee approval + Medical Sciences University coordination + GCP compliance; substantial Iranian academic-medical-centre clinical-research capacity.	IFDA target review: 60-90 calendar days for CTA; substantial Iranian clinical-trials hub role + biosimilar comparability-trial capacity.
Compassionate Use + Named Patient	Compassionate-use + named-patient access frameworks for unmet-medical-need patients per IFDA guidance.	Expedited IFDA review on case-by-case basis.
Orphan Drug Designation	IFDA orphan-drug designation framework substantively aligned with EMA orphan-drug framework.	IFDA designation review with substantial regulatory + reimbursement benefits.
Pricing + Insurance Reimbursement Coordination	Pricing-control framework via IFDA Pricing Commission + reference-pricing methodology + Food and Drug Organization Insurance + Iranian Social Security Organization + Salamat Insurance Reimbursement Commission coordination.	Parallel pricing + reimbursement review post-registration; substantial Iranian-localised + WHO PQ preferential treatment.

04IFDA Reference Laboratories + GMP Inspection + PIC/S Member capability

IFDA Reference Laboratories include the IFDA central reference laboratories + Razi Vaccine and Serum Research Institute (Karaj — substantial vaccine lot-release + biological QC capacity) + Pasteur Institute of Iran (Tehran — substantial vaccine + biological + diagnostics capacity) with substantial ISO/IEC 17025 + WHO PQ-Lab capacity. IFDA is a PIC/S Member (since 2018) enabling substantial mutual-recognition agreements with EU + UK + Switzerland + Japan + Australia + Canada + Singapore + Indonesia + Malaysia + Korea + Türkiye + Israel + Argentina + USA-FDA bilateral inspections subject to sanctions-environment compliance. The IFDA Pharmaceutical Inspection Office conducts substantial inspections of Iranian-domestic + foreign manufacturing facilities both domestically + via PIC/S mutual-recognition + bilateral arrangements.

ISO/IEC 17025 — IFDA Reference Laboratories + Razi Institute + Pasteur Institute operate with substantial ISO/IEC 17025 accredited scope.
WHO PQ-Lab — Razi Institute + Pasteur Institute + IFDA Reference Laboratories WHO PQ-Lab participating; substantial WHO PQ programme participation.
PIC/S Member (since 2018) — substantial mutual-recognition agreements with EU + UK + Switzerland + Japan + Australia + Canada + Singapore + Indonesia + Malaysia + Korea + Türkiye + Israel + Argentina + USA-FDA bilateral inspections subject to sanctions-environment compliance; one of the most operationally significant IFDA capabilities for foreign-manufacturer GMP-inspection coordination.
Vaccine lot release — Razi Institute (Karaj) + Pasteur Institute of Iran (Tehran) substantial vaccine lot-release testing for Iranian National Immunisation Programme + substantial Iranian-domestic vaccine-manufacturing capacity + WHO PQ programme.
Pharmaceutical pre-registration + post-market testing — pre-registration quality testing + substantial post-market surveillance + targeted enforcement testing.
Medical-device + IVD testing — pre-market + post-market quality testing.
Cosmetic-product + dietary-supplement + food testing — safety + ingredient compliance testing.
Counterfeit-medicine forensics — substantial forensic analytical support for IFDA + Iranian National Police + Iranian Customs + WHO Global Surveillance & Monitoring System contributions; substantial counterfeit-medicine quality risk given sanctions-environment supply-chain disruption + cross-border smuggling.
Substantial biosimilar QC capacity — substantial Iranian biosimilar-industry QC capacity supporting Cinnagen + AryoGen + Pooyesh Darou + Samenpharmed + Orchid Pharmed biosimilar comparability + characterisation + lot-release.
Capacity-building — substantial WHO + bilateral-donor capacity-building programmes + training for Iranian pharmaceutical analysts.
GMP Inspectorate — substantial PIC/S Member capability for Iranian + foreign manufacturing facility GMP inspections both domestically + via PIC/S mutual-recognition + bilateral arrangements; substantial export-market support for ~120+ Iranian-domestic manufacturers including biosimilar + vaccine + generic capacity.
Iranian domestic manufacturer support — supports substantial Iranian-domestic pharmaceutical-manufacturing industry including ~120+ manufacturers + ~200+ pharmaceutical-manufacturing facilities covering ~97% of domestic consumption by volume including Cinnagen + AryoGen + Sobhan + Osvah + Pars Daru + Tehran Chemie + Daru Pakhsh + Aburaihan + Loghman + Alborz Daru + Iran Hormone + Tofigh Daru + Razi Vaccine and Serum Research Institute + Pasteur Institute of Iran + Exir Pharmaceutical.

05Medical Device + IVD + Cosmetic + Dietary Supplement Registration

IFDA medical-device + IVD regulation operates under IFDA Medical Device Regulation substantively incorporating EU MDR 2017/745 + IVDR 2017/746 + IMDRF elements. Iran has substantial medical-device-manufacturing capacity with ~80+ Iranian-domestic medical-device manufacturers covering substantial portions of domestic consumption + regional EMRO + Central Asian + EAEU export markets.

Risk-based Classification (Class I / IIa / IIb / III) — substantively aligned with EU MDR; IVDs classified under separate framework substantively aligned with EU IVDR.
Iranian Authorised Representative — Iran-resident legal entity required for foreign manufacturers; bears post-market vigilance responsibility + IFDA regulatory interface.
ISO 13485:2016 — recognised by IFDA as QMS evidence framework; substantial Iranian-domestic manufacturer ISO 13485 capacity.
Reliance pathways — IFDA accepts CE Mark + FDA 510(k) + FDA PMA + Health Canada + TGA + Swissmedic + MFDS + Japan + Russian + Chinese + Indian + Turkish-approval evidence as supporting evidence subject to sanctions-environment compliance; CE Mark + Russian + Chinese substantially central given EAEU + Belt and Road operational context.
Post-market vigilance — IFDA operates medical-device adverse-event reporting; reporting timelines substantively aligned with EU MDR + IMDRF Adverse Event Reporting Codes.
IVD Reactivigilance — IFDA operates IVD reactivigilance reflecting Iran's substantial clinical-laboratory infrastructure including academic-medical-centres + Medical Sciences University-affiliated hospitals.
Cosmetic Notification — cosmetics require IFDA Cosmetic Notification + Persian labelling; INCI-aligned ingredient listing + safety substantiation; substantively EU Cosmetics Regulation elements-aligned framework.
Dietary Supplement Registration — IFDA Dietary Supplements framework.
Traditional + Complementary Medicines — distinctive Iranian traditional Persian medicine (طب سنتی ایرانی) framework recognising substantial Iranian-traditional-medicine heritage including substantial Avicennian medical heritage.
Substantial Export-Market Support — IFDA provides substantial Iranian-domestic manufacturer export-market support to EMRO + Central Asian + EAEU + Belt and Road + Iraq + Syria + Afghanistan + Pakistan + sub-Saharan African markets via GMP Certificate + Free Sale Certificate + Certificate of Pharmaceutical Product issuance.

06IFDA Pharmacovigilance + Iranian ADR Centre

IFDA operates the Iranian Pharmacovigilance Centre (مرکز ثبت و بررسی عوارض ناخواسته داروها — ADR Centre). Iran is a WHO Programme for International Drug Monitoring (PIDM) member + contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre (UMC). The Iranian ADR Centre coordinates with Medical Sciences Universities + academic-medical-centres + Iran Pharmacists Association + Iranian Medical Council + Marketing Authorisation Holders. Iranian pharmacovigilance is uniquely shaped by substantial regional pharmaceutical-hub status + substantial biosimilar + biotechnology + vaccine surveillance commitments + substantial sanctions-environment supply-chain quality-risk monitoring + substantial 31-province Vice-Chancellor for Food and Drug Affairs provincial network.

Iranian Pharmacovigilance Centre (مرکز ثبت و بررسی عوارض ناخواسته داروها) — coordinated by IFDA.
WHO PIDM Member — Iran contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre.
Iranian PV Network — coordinated national network with effector centres in major Iranian Medical Sciences Universities (Tehran + Shahid Beheshti + Iran + Isfahan + Mashhad + Shiraz + Tabriz + Ahvaz Jundishapur + Kerman + Mazandaran + Guilan + Zahedan + Kermanshah + Yazd + Hamadan + Qazvin + Babol + Ardabil + Birjand + Bandar Abbas + Ilam + Lorestan + Sanandaj + Semnan + Urmia + 31-province Vice-Chancellor for Food and Drug Affairs structures) + Iran Pharmacists Association + Marketing Authorisation Holders.
ADR Reporting — IFDA operates ADR reporting via Iranian Pharmacovigilance Centre portal; available for healthcare professionals + consumers + Marketing Authorisation Holders.
E2B(R3) ICSR — IFDA accepts E2B(R3) format ICSR submissions; 15-day SUSAR reporting timeline for clinical trials + post-market substantively aligned with ICH E2 + WHO PV guidance.
PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2).
Risk Management Plans (RMP) — IFDA requires ICH E2E-aligned Pharmacovigilance Plan + Risk Management Plan for new drugs + biosimilars + vaccines + ATMPs + high-risk products; substantial Iranian biosimilar Risk Management Plan capacity.
Active surveillance — Iranian Pharmacovigilance Centre operates substantial active-surveillance programmes for COVID-19 vaccines + childhood immunisation + biosimilars + ATMPs + high-risk products including substantial Iranian-domestic COVID-19 vaccine surveillance.
AEFI Surveillance — Iranian vaccine adverse-event surveillance aligned with WHO methodology; central to Iranian National Immunisation Programme + substantial Razi + Pasteur Institute vaccine programmes + UNICEF + WHO-supported immunisation campaigns.
Matériovigilance + Cosmétovigilance — IFDA operates parallel matériovigilance for medical devices + cosmétovigilance for cosmetics.
Counterfeit + substandard medicine surveillance — substantial role given Iran's sanctions-environment supply-chain disruption + cross-border smuggling + regional Afghan + Iraqi + Pakistani border-trade quality risks.
PIC/S Mutual-Recognition — substantial PIC/S Member pharmacovigilance + GMP-inspection mutual-recognition subject to sanctions-environment compliance.
Biosimilar Pharmacovigilance — substantial Iranian biosimilar-industry pharmacovigilance commitments supporting Cinnagen + AryoGen + Pooyesh Darou + Samenpharmed + Orchid Pharmed biosimilar post-market surveillance.

07IFDA international engagement

PIC/S Member (since 2018) — one of the most operationally significant IFDA capabilities; substantial mutual-recognition agreements with EU + UK + Switzerland + Japan + Australia + Canada + Singapore + Indonesia + Malaysia + Korea + Türkiye + Israel + Argentina + USA-FDA bilateral inspections subject to sanctions-environment compliance.
WHO PIDM Member — Iran contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre.
WHO PQ Programme Participant — Iran-manufactured medicines + vaccines + biosimilars via WHO PQ enable substantial UN-agency humanitarian procurement + LMIC market access notably for Cinnagen + AryoGen biosimilars + Razi + Pasteur Institute vaccines.
WHO EMRO — substantial WHO Eastern Mediterranean Regional Office cooperation; substantial regional pharmaceutical regulatory cooperation.
ECO Member State — Economic Cooperation Organization (10 Member States — Iran + Türkiye + Pakistan + Afghanistan + Azerbaijan + Kazakhstan + Kyrgyzstan + Tajikistan + Turkmenistan + Uzbekistan); substantial regional ECO pharmaceutical regulatory cooperation.
ICH Observer — substantial ICH guideline implementation in Iranian regulatory practice including ICH Q1-Q14 + E1-E20 + M1-M11 + S1-S12.
Russian Roszdravnadzor Bilateral — substantial EAEU + neighbour bilateral cooperation reflecting Iran-Russia pharmaceutical-trade growth + sanctions-environment EAEU pharmaceutical-import opportunity.
Chinese NMPA Bilateral — Belt and Road Initiative substantial bilateral pharmaceutical cooperation + substantial China-Iran pharmaceutical + API trade reflecting sanctions-environment supply-chain reorientation.
Indian CDSCO Bilateral — substantial trade-driven cooperation reflecting India as substantial pharmaceutical + API import source for Iran.
Turkish TİTCK Bilateral — regional EMEA neighbour + substantial bilateral cooperation reflecting Iran-Türkiye pharmaceutical-trade + PIC/S Member peer cooperation.
Iraqi MoH + Syrian MoH Bilateral — substantial bilateral cooperation reflecting Iran-Iraq + Iran-Syria pharmaceutical-trade; Iran is one of the largest pharmaceutical export sources to Iraq + Syria.
Pakistani DRAP + Afghan MoPH Bilateral — substantial regional bilateral cooperation reflecting cross-border pharmaceutical-trade + humanitarian operations.
Central Asian + Caucasus Regulators Bilateral — substantial bilateral cooperation with Azerbaijan + Turkmenistan + Tajikistan reflecting Iran's regional pharmaceutical export hub role.
ICDRA + EMRO + IMDRF + IPRP participation — substantial International Conference of Drug Regulatory Authorities + WHO EMRO + International Medical Device Regulators Forum + International Pharmaceutical Regulators Programme participation.
International Generic and Biosimilar Medicines Association (IGBA) — substantial international generic + biosimilar cooperation reflecting Iran's substantial biosimilar industry.
Donor + Bilateral Cooperation — substantial bilateral cooperation with WHO + UNICEF + UN-agency humanitarian programmes + bilateral pharmaceutical-regulatory + healthcare programming subject to sanctions-environment compliance.

08Common IFDA registration issues + missteps

Sanctions-environment compliance under-planned — most operationally significant feature of Iranian pharmaceutical market access; substantial US OFAC + EU + UK OFSI sanctions including humanitarian-exemption General Licenses for medicines + medical devices + financial-channel compliance frequently under-planned by foreign manufacturers leading to substantial transactional + financial-channel + insurance + shipping + banking compliance failures.
PIC/S Member (since 2018) mutual-recognition under-leveraged — substantial PIC/S Member mutual-recognition substantially under-leveraged for GMP-inspection coordination subject to sanctions-environment compliance.
Iranian Authorised Representative not properly designated — application rejected at IFDA intake or post-approval compliance failure; Iranian Authorised Representative must be Iran-resident legal entity with appropriate licensure.
Persian (Farsi) labelling deficiencies — Persian required; many applicants provide insufficient Persian-language patient leaflet content.
IFDA GMP gaps — applicants assuming EU GMP / PIC/S GMP / FDA GMP compliance is automatically sufficient without addressing Iran-specific IFDA GMP clarifications.
Iran climate-zone stability data missing — Iran spans Climate Zone II coastal Caspian (Rasht + Sari + Anzali) + Persian Gulf (Bushehr + Bandar Abbas + Ahvaz) + IVa interior (Tehran + Isfahan + Shiraz + Mashhad + Tabriz) + IVb arid Central Plateau (Yazd + Kerman + Zahedan + Birjand); requires substantial zonal-specific stability data.
Local-Industry-Protected Status not addressed — distinctive Iranian-domestic pharmaceutical-manufacturing localisation policy historically restricting registration where Iranian-domestic equivalents exist; substantial Iranian-localised manufacturing investment + technology transfer + joint-venture pathways frequently under-leveraged.
Pricing + Insurance Reimbursement Coordination not planned — parallel pricing + reimbursement review post-registration via Food and Drug Organization Insurance + Iranian Social Security Organization + Salamat Insurance frequently under-planned.
WHO PQ programme opportunity not leveraged — Iranian-domestic manufacturers notably Cinnagen + AryoGen biosimilars + Razi + Pasteur Institutes vaccines can leverage substantial WHO PQ programme participation for UN-agency humanitarian procurement + LMIC market access.
EMA + SRA + WHO PQ reliance under-utilised — substantial EMA + Stringent Regulatory Authority + WHO PQ reliance substantially under-utilised subject to sanctions-environment compliance.
Trade-partner reliance (Roszdravnadzor / NMPA / CDSCO / TİTCK / DRAP) under-utilised — substantial trade-driven reliance reflecting Iran's substantial sanctions-environment supply-chain reorientation to EAEU + Belt and Road + India + Türkiye + Pakistan + Afghanistan + Central Asian trade partners frequently under-utilised.
Bioequivalence centres + biowaiver — IFDA BE Guidance provides BCS-based biowaivers; applicants frequently submit BE studies where biowaivers would suffice.
Counterfeit + substandard medicine quality risks under-monitored — Iran's sanctions-environment supply-chain disruption + cross-border Afghan + Iraqi + Pakistani border-trade smuggling create substantial counterfeit + substandard medicine quality risks requiring substantial post-market quality surveillance.
Substantial Iranian export-market support not leveraged — substantial IFDA GMP Certificate + Free Sale Certificate + Certificate of Pharmaceutical Product capacity substantially under-leveraged for foreign-manufacturer Iranian-localised production + EMRO + Central Asian + EAEU + Belt and Road + Iraq + Syria + Afghanistan + Pakistan + sub-Saharan Africa export markets.
Substantial Iranian biosimilar + biotechnology + vaccine + Royan Institute ATMP + Pasteur Institute + Razi Institute innovation industry partnership opportunities not leveraged — substantial Iranian biosimilar + biotechnology + vaccine + ATMP innovation industry partnership opportunities substantially under-leveraged.
Substantial Iranian academic-medical-centre clinical-research capacity not leveraged — substantial 88-million-population + 31-province Medical Sciences Universities clinical-research capacity substantially under-leveraged.
Variations strategy not planned — variations procedure with Iran-specific timelines + fee structure.
Registration renewal timing missed — 5-year renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration.

09How V5 Ultimate supports IFDA readiness

V5 Ultimate provides the operational infrastructure Iranian + foreign-supplier sites need for the Law on the Establishment of the Iran FDA 1392/2013 + Law on Pharmaceutical Affairs 1334/1955 + IFDA Drug Registration Regulation + IFDA GMP + IFDA Medical Device Regulation + IFDA Cosmetics Regulation + PIC/S Member mutual-recognition + WHO PQ programme participation + WHO EMRO + ECO + Iranian Pharmacovigilance Centre + substantial Iranian-domestic manufacturer export-market support to EMRO + Central Asian + EAEU + Belt and Road + Iraq + Syria + Afghanistan + Pakistan + sub-Saharan Africa markets + substantial sanctions-environment compliance support.

IFDA GMP control framework — PIC/S + ICH Q7 + WHO TRS 986 Annex 2 + EU GMP elements-aligned controls with ALCOA+ data-integrity + Iran-specific clarifications + Climate Zone II coastal Caspian + Persian Gulf + IVa interior + IVb arid Central Plateau stability monitoring.
IFDA registration dossier packaging — Iran CTD-aligned dossier structure with Iran Module 1 specifics + Module 3 stability + Persian patient leaflet + Iranian Authorised Representative declarations + IFDA Drug Registration Regulation framework + substantial EU Module reuse.
Sanctions-environment compliance workflow — most operationally significant feature; substantial US OFAC + EU + UK OFSI sanctions-environment compliance packaging including humanitarian-exemption General Licenses for medicines + medical devices + financial-channel compliance + insurance + shipping + banking compliance support.
PIC/S Member mutual-recognition workflow — substantial PIC/S Member mutual-recognition packaging for GMP-inspection coordination subject to sanctions-environment compliance.
WHO PQ programme workflow — Iranian-manufactured medicines + vaccines + biosimilars WHO PQ submission packaging for substantial UN-agency humanitarian procurement + LMIC market access notably for Cinnagen + AryoGen biosimilars + Razi + Pasteur Institutes vaccines.
EMA + SRA + WHO PQ reliance workflow — IFDA-EMA + IFDA-FDA + IFDA-Health Canada + TGA + Swissmedic + MHRA + MFDS + PMDA + WHO PQ reliance packaging subject to sanctions-environment compliance.
Local-Industry-Protected Status workflow — distinctive Iranian-domestic pharmaceutical-manufacturing localisation packaging + Iranian-localised manufacturing investment + technology transfer + joint-venture pathway support.
Pricing + Insurance Reimbursement Coordination workflow — IFDA Pricing Commission + Food and Drug Organization Insurance + Iranian Social Security Organization + Salamat Insurance coordination packaging for parallel pricing + reimbursement review post-registration.
Trade-partner reliance workflow (Roszdravnadzor / NMPA / CDSCO / TİTCK / DRAP) — substantial sanctions-environment trade-partner reliance packaging reflecting Iran's substantial supply-chain reorientation to EAEU + Belt and Road + India + Türkiye + Pakistan + Afghanistan + Central Asian trade partners.
Iranian Authorised Representative workflow — foreign-manufacturer Iranian Authorised Representative designation + role-management + Iran-specific post-market surveillance.
Iranian clinical-trial workflow — IFDA CTA + Tehran + Shahid Beheshti + Iran + Isfahan + Mashhad + Shiraz + Tabriz / Royan Institute / Pasteur Institute / Razi Institute Medical Sciences University Ethics Committee coordination + Iranian SUSAR reporting via Iranian Pharmacovigilance Centre; substantial Iranian clinical-trials hub role + biosimilar comparability-trial capacity.
Iranian Pharmacovigilance Centre integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Iranian ICSR + Iranian PV Network coordination + VigiBase upload + Risk Management Plan packaging + AEFI vaccine adverse-event reporting + substantial biosimilar pharmacovigilance commitments.
Matériovigilance + Cosmétovigilance workflow — parallel matériovigilance + cosmétovigilance packaging.
Medical-device + IVD + cosmetic + dietary-supplement + traditional-Persian-medicine workflow — IFDA frameworks dossier packaging + Class I-III classification + ISO 13485 + Iranian Authorised Representative + post-market vigilance.
Counterfeit + substandard medicine surveillance workflow — Iran's sanctions-environment supply-chain disruption + cross-border Afghan + Iraqi + Pakistani border-trade quality-risk monitoring + WHO Global Surveillance & Monitoring System integration.
Biosimilar + ATMP workflow — IFDA biosimilar + ATMP registration packaging substantively aligned with EMA + Royan Institute frameworks; substantial Iranian biosimilar + Royan Institute ATMP-innovation industry support.
Vaccine + Razi + Pasteur Institute workflow — substantial Iranian vaccine-manufacturing capacity packaging including Razi Institute (Karaj) + Pasteur Institute of Iran (Tehran) + Iranian National Immunisation Programme support.
Iranian export-market support workflow — substantial IFDA GMP Certificate + Free Sale Certificate + Certificate of Pharmaceutical Product capacity packaging for foreign-manufacturer Iranian-localised production + EMRO + Central Asian + EAEU + Belt and Road + Iraq + Syria + Afghanistan + Pakistan + sub-Saharan Africa export markets.
EMRO + Central Asian + EAEU + Belt and Road regional bridging — for companies operating across EMRO + Central Asian + EAEU + Belt and Road jurisdictions, V5 surfaces IFDA + Iraq MoH + Syria MoH + Türkiye TİTCK + Pakistan DRAP + Afghan MoPH + Roszdravnadzor + NMPA + CDSCO + Central Asian harmonised dossier-element reuse alongside national-specific extensions + sanctions-environment compliance.

Frequently asked questions

Q.What does the Iran FDA regulate?+

The Iran Food and Drug Administration (IFDA — سازمان غذا و دارو) — operating as autonomous deputy organisation of the Ministry of Health and Medical Education (MoHME) — is the Islamic Republic of Iran's national regulatory authority for human medicines (drugs, biologicals, biosimilars, vaccines, ATMPs), medical devices + IVDs + cosmetics + dietary supplements + food + traditional + complementary medicines + pharmacy practice + controlled substances + clinical trials under the Law on the Establishment of the Iran FDA 1392/2013 + Law on Pharmaceutical Affairs 1334/1955 + Food, Drugs and Sanitary Materials Law 1346/1967. The IFDA operates Pharmaceutical Affairs Office + Pharmaceutical Inspection Office + Medical Devices Office + Pharmacy Practice Office + Cosmetics + Dietary Supplements Office + Food Office + Controlled Substances Office + Pharmacovigilance Centre + Clinical Trials Office + Reference Laboratories. The IFDA is a PIC/S Member (since 2018) + WHO PIDM Member + WHO PQ programme participant + ECO Member State.

Q.How does Iran's sanctions environment affect pharmaceutical market access?+

Iran operates under substantial US OFAC + EU + UK OFSI sanctions including humanitarian-exemption General Licenses for medicines + medical devices + financial-channel compliance — this is the most operationally significant feature of Iranian pharmaceutical market access. The humanitarian-exemption General Licenses (notably US OFAC General License 8) permit medicines + medical devices + cosmetics + food transactions but require substantial financial-channel compliance (typically via Swiss Humanitarian Trade Arrangement or analogous structures), insurance, shipping, banking + due-diligence frameworks. The sanctions environment has driven substantial Iranian-domestic-manufacturing self-sufficiency policy (~97% domestic volume + ~70% domestic value coverage historically) + substantial EAEU + Belt and Road + India + Türkiye + Iraq + Syria + Pakistan + Afghanistan + Central Asian trade-partner reorientation. Foreign manufacturers + sponsors targeting Iran require substantial sanctions-environment compliance planning including humanitarian-exemption General License qualification + financial-channel arrangements + insurance + shipping + banking + due-diligence frameworks.

Q.How long does IFDA registration take?+

Standard timelines: new drug registration 270-360 calendar days; generic registration 180-270 calendar days; biosimilar registration 270-360 calendar days; vaccine registration 180-360 calendar days; ATMP registration 270-360 calendar days; SRA + WHO PQ reliance substantially reduced subject to sanctions-environment compliance; WHO PQ programme participation for Iranian-domestic manufacturers; Local-Industry-Protected Status pathway with IFDA + Syndicate of Iranian Pharmaceutical Industries coordinated review; trade-partner reliance with Roszdravnadzor + NMPA + CDSCO + TİTCK + DRAP substantially reduced; Variations 30-180 calendar days; Clinical Trial Application 60-90 calendar days; Compassionate Use + Named Patient expedited; Orphan Drug Designation; Pricing + Insurance Reimbursement Coordination parallel review post-registration. Sanctions-environment compliance planning + PIC/S Member mutual-recognition + EMA + SRA + WHO PQ reliance + Local-Industry-Protected Status pathway + trade-partner reliance are essential acceleration strategies for sponsors targeting Iran.

Q.What is the significance of Iran's PIC/S Member status (since 2018)?+

IFDA PIC/S Member status (since 2018) is one of the most operationally significant IFDA capabilities. PIC/S Membership enables substantial mutual-recognition agreements with EU + UK + Switzerland + Japan + Australia + Canada + Singapore + Indonesia + Malaysia + Korea + Türkiye + Israel + Argentina + USA-FDA bilateral inspections subject to sanctions-environment compliance. This substantially reduces GMP-inspection burden + cost + timeline for foreign manufacturers operating Iranian-domestic facilities + for Iranian-domestic manufacturers (notably Cinnagen + AryoGen biosimilars + Razi + Pasteur Institutes vaccines) exporting to PIC/S Member markets. PIC/S Member status enables substantial IFDA GMP Certificate + Free Sale Certificate + Certificate of Pharmaceutical Product issuance for substantial Iranian-domestic manufacturer export-market support to EMRO + Central Asian + EAEU + Belt and Road + Iraq + Syria + Afghanistan + Pakistan + sub-Saharan Africa markets.

Q.Is the IFDA part of PIC/S + WHO PIDM + WHO PQ?+

Yes — IFDA is a PIC/S Member (since 2018) — one of the most operationally significant IFDA capabilities subject to sanctions-environment compliance; a WHO PIDM Member contributing substantial ADR data to VigiBase via Uppsala Monitoring Centre; a WHO PQ programme participant enabling substantial UN-agency humanitarian procurement + LMIC market access via Iranian-domestic manufacturers notably Cinnagen + AryoGen biosimilars + Razi + Pasteur Institutes vaccines; ECO Member State (10 Member States — Iran + Türkiye + Pakistan + Afghanistan + Azerbaijan + Kazakhstan + Kyrgyzstan + Tajikistan + Turkmenistan + Uzbekistan); ICH Observer; substantial WHO EMRO cooperation; substantial bilateral cooperation with Russian Roszdravnadzor + Chinese NMPA + Indian CDSCO + Turkish TİTCK + Iraqi MoH + Syrian MoH + Pakistani DRAP + Afghan MoPH + Central Asian + Caucasus regulators; ICDRA + EMRO + IMDRF + IPRP + IGBA participation.

Q.What's distinctive about Iran's pharmaceutical environment as a regional biosimilar + vaccine hub?+

Iran's pharmaceutical environment is uniquely characterised by: substantial regional pharmaceutical-manufacturing hub status — ~120+ Iranian-domestic manufacturers + ~200+ pharmaceutical-manufacturing facilities covering ~97% of domestic consumption by volume + ~70% by value historically including Cinnagen + AryoGen + Sobhan + Osvah + Pars Daru + Tehran Chemie + Daru Pakhsh + Aburaihan + Loghman + Alborz Daru + Iran Hormone + Tofigh Daru + Razi Vaccine and Serum Research Institute + Pasteur Institute of Iran + Exir Pharmaceutical; substantial biotechnology + biosimilar industry — Cinnagen is one of the largest biosimilar manufacturers in EMRO + one of the substantial global biosimilar manufacturers, AryoGen Pharmed + Pooyesh Darou + Samenpharmed + Orchid Pharmed substantial capacity; substantial vaccine-manufacturing capacity via Razi Vaccine and Serum Research Institute (Karaj) + Pasteur Institute of Iran (Tehran) covering BCG + DTP + measles + rubella + hepatitis B + COVID-19 vaccines; substantial Royan Institute stem-cell + reproductive-biology + ATMP research capacity; substantial sanctions-environment context under US OFAC + EU + UK OFSI sanctions with humanitarian-exemption General Licenses driving substantial domestic-manufacturing self-sufficiency + EAEU + Belt and Road + India + Türkiye + Iraq + Syria + Pakistan + Afghanistan + Central Asian trade-partner reorientation; PIC/S Member status (since 2018); WHO PQ programme participation; ECO Member State; Persian (Farsi) labelling; Climate Zone II coastal Caspian + Persian Gulf + IVa interior + IVb arid Central Plateau stability requirements. For foreign manufacturers, Iran is one of the most operationally significant pharmaceutical regulators globally for biosimilar + vaccine + ATMP partnership + EMRO + Central Asian + EAEU + Belt and Road market access via Iranian-localised production + PIC/S Member mutual-recognition + WHO PQ programme participation + sanctions-environment compliant pathways.